Skip to content
value.today
BrainsWay Ltd. logo

BrainsWay Ltd.

BWAY
$602 Mmarket cap on Aug 1, 2026+389.1% since Jan 2024
Compare
World rank
#11,774
Revenue
$41 M
For year ending December-2024
Net income
$3 M
7.1% margin
SEC filing
Employees
—

BrainsWay Ltd. in brief

BrainsWay Ltd. is a listed company in the Healthcare sector, based in Israel. It was founded in 2003. Its market value was $602 M on 1 August 2026, which makes it the 11,774th largest listed company in the world and the 128th largest in Israel on this site. In the year to December 2024 it had sales of $41 M and a net profit of $3 M, about 7 cents of profit for every dollar of sales. Hadar Levy is its chief executive. Its shares trade under the symbol BWAY (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About BrainsWay Ltd.

BrainsWay Ltd. (Hebrew: בריינסוויי) is an international company that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation (Deep TMS) as a non-invasive treatment for depression, OCD, and smoking addiction. The company was founded in 2003 and has offices in the US and Jerusalem.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

BrainsWay Ltd. timeline

3 events, 2003–2019
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. 2011
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2019
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 17 April 2019; shares registered for exchange trading on 11 April 2019.

Events of BrainsWay Ltd. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$252 M$504 M$756 M$1.0 B2020202120222023202420252026

World rank over time

▲ up 6,868 places since 2020
2020-01-01: #18384#18,38420202021-01-01: #19057#19,05720212022-01-07: #21472#21,47220222022-12-25: #26807#26,80720222023-07-30: #26286#26,28620232024-01-05: #20393#20,39320242026-03-08: #4936#4,93620262026-08-01: #11516#11,5162026

Rank in Israel: #193 (Jan 2020) · #244 (Jan 2021) · #268 (Jan 2022) · #332 (Dec 2022) · #354 (Jul 2023) · #232 (Jan 2024) · #12 (Mar 2026) · #129 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
206.0×
Price / sales (TTM)
14.7×
Price / book
9.7×
Free cash flow yield
-0.2%
Net margin (TTM)
7.1%
Operating margin
3.4%
Return on equity
4.7%
Liabilities / assets
33.9%
Net debt
$-7M
Revenue growth
+29.1%
R&D / revenue
17.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $11M, net income $-7M$11MFY17Fiscal year ending Dec 2018: revenue $16M, net income $-6M$16MFY18Fiscal year ending Dec 2019: revenue $23M, net income $-10M$23MFY19Fiscal year ending Dec 2020: revenue $22M, net income $-5M$22MFY20Fiscal year ending Dec 2021: revenue $30M, net income $-6M$30MFY21Fiscal year ending Dec 2022: revenue $27M, net income $-13M$27MFY22Fiscal year ending Dec 2023: revenue $32M, net income $-4M$32MFY23Fiscal year ending Dec 2024: revenue $41M, net income $3M$41MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$41M+29.1%$1M$3M7.1%
Dec 2023$32M+16.9%$-5M$-4M-13.2%
Dec 2022$27M-8.4%$-13M$-13M-49.1%
Dec 2021$30M+34.5%$-5M$-6M-21.8%
Dec 2020$22M-4.5%$-5M$-5M-24.4%
Dec 2019$23M+40.9%$-8M$-10M-44.7%
Dec 2018$16M+47.2%$-5M$-6M-39.5%
Dec 2017$11M—$-7M$-7M-63.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$10M——$0.05—
Dec 2023$1M——$-0.13—
Dec 2022$-10M——$-0.40—
Dec 2021$1M$2M$-1M$-0.21—
Dec 2020$-1M$2M$-4M——
Dec 2019$-7M$3M$-11M——
Dec 2018$-4M$2M$-6M——
Dec 2017$-3M$1M$-4M——

SEC filings

Official filings of BrainsWay Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
$41 M
Operating income
$1 M
Net income
$3 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$94 M
Total liabilities
$32 M
Total equity
$62 M

As of December-2024

Top 65 institutional investors in BrainsWay Ltd.#

As of Sep 30, 2026
65 institutions held 11.4 M shares (about 28.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 24.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in BrainsWay Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
1Valor Management LLC5,314,9500 (0.00%)13.45%$70 MNov 16, 2026
2Masters Capital Management LLC1,246,099-253,901 (-16.93%)3.15%$16 MNov 16, 2026
3Acadian Asset Management LLC769,366-38,565 (-4.77%)1.95%$10 MNov 9, 2026
4Essex Investment Management Co LLC574,818-17,788 (-3.00%)1.46%$8 MOct 19, 2026
5Renaissance Technologies LLC445,520-30,400 (-6.39%)1.13%$6 MNov 12, 2026
6Cresset Asset Management, LLC314,9240 (0.00%)0.80%$4 MNov 16, 2026
7HWG Holdings LP253,050New0.64%$3 MOct 8, 2026
8Morgan Stanley250,713+61,745 (+32.67%)0.63%$3 MNov 13, 2026
9Y.D. More Investments Ltd224,382-13,051 (-5.50%)0.57%$3 MNov 2, 2026
10Eagle Global Advisors LLC182,6060 (0.00%)0.46%$2 MNov 2, 2026
11Legato Capital Management LLC176,569-21,066 (-10.66%)0.45%$2 MNov 10, 2026
12ARK Investment Management LLC146,850+4,350 (+3.05%)0.37%$2 MNov 13, 2026
13Jpmorgan Chase & Co127,019+30,212 (+31.21%)0.32%$2 MNov 12, 2026
14SEI Investments Co119,7170 (0.00%)0.30%$2 MNov 10, 2026
15Walleye Capital LLC106,834New0.27%$1 MNov 13, 2026
16Two Sigma Investments, LP105,859+6,314 (+6.34%)0.27%$1 MNov 16, 2026
17Royce & Associates LP97,0330 (0.00%)0.25%$1 MNov 9, 2026
18Huntleigh Advisors, Inc.91,072+3,766 (+4.31%)0.23%$1 MNov 3, 2026
19Tidal Investments LLC87,375-1,873 (-2.10%)0.22%$1 MNov 13, 2026
20Bank Of America Corp /de/61,287New0.16%$1 MNov 16, 2026
21Wells Fargo & Company/mn58,980+3,351 (+6.02%)0.15%$1 MNov 16, 2026
22Qube Research & Technologies Ltd51,485New0.13%$1 MNov 13, 2026
23Sigma Planning Corp50,635-49,800 (-49.58%)0.13%$1 MOct 23, 2026
24Voleon Capital Management LP44,439+19,628 (+79.11%)0.11%$1 MNov 16, 2026
25Bullseye Asset Management LLC41,4820 (0.00%)0.10%$1 MNov 13, 2026
Show all 65: investors 26 to 65
Institutional investors 26 to 65 in BrainsWay Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
26Man Group plc40,311+12,837 (+46.72%)0.10%$1 MNov 16, 2026
27UBS Group AG35,074-66,003 (-65.30%)0.09%$0 MNov 10, 2026
28Goldman Sachs Group Inc33,067-59,024 (-64.09%)0.08%$0 MNov 16, 2026
29Rhumbline Advisers32,275-5,234 (-13.95%)0.08%$0 MNov 10, 2026
30State of Wyoming32,015-6,730 (-17.37%)0.08%$0 MOct 28, 2026
31Quadrature Capital Ltd29,152-33,942 (-53.80%)0.07%$0 MNov 13, 2026
32Stifel Financial Corp22,000New0.06%$0 MNov 12, 2026
33BNP Paribas Financial Markets21,576New0.05%$0 MNov 12, 2026
34Citadel Advisors LLC21,196-26,323 (-55.39%)0.05%$0 MNov 16, 2026
35LPL Financial LLC18,800New0.05%$0 MNov 6, 2026
36Commonwealth Of Pennsylvania Public School Empls Retrmt Sys17,4700 (0.00%)0.04%$0 MNov 3, 2026
37Crossmark Global Holdings, Inc.14,950-10,401 (-41.03%)0.04%$0 MOct 21, 2026
38Royal Bank Of Canada14,541-399 (-2.67%)0.04%$0 MNov 16, 2026
39Geode Capital Management, LLC13,7050 (0.00%)0.03%$0 MNov 6, 2026
40HRT Financial LP13,331New0.03%$0 MNov 13, 2026
41Calamos Advisors LLC10,255New0.03%$0 MNov 2, 2026
42State of Tennessee, Department of Treasury8,8120 (0.00%)0.02%$0 MNov 16, 2026
43BlackRock, Inc.5,948+4,264 (+253.21%)0.02%$0 MNov 13, 2026
44Osaic Holdings, Inc.4,569+1 (+0.02%)0.01%$0 MNov 12, 2026
45GAMMA Investing LLC3,6340 (0.00%)0.01%$0 MOct 8, 2026
46Fifth Third Bancorp2,466New0.01%$0 MNov 5, 2026
47Montag A & Associates Inc2,459New0.01%$0 MOct 29, 2026
48NewEdge Advisors, LLC1,801-17,029 (-90.44%)0.00%$0 MNov 13, 2026
49Citigroup Inc1,717+1,714 (+57133.33%)0.00%$0 MNov 4, 2026
50TD Waterhouse Canada Inc.1,4300 (0.00%)0.00%$0 MOct 16, 2026
51Barclays PLC1,352-83 (-5.78%)0.00%$0 MNov 6, 2026
52Lanark Financial, Inc.1,1000 (0.00%)0.00%$0 MOct 26, 2026
53Simplex Trading, LLC461New0.00%$0 MNov 4, 2026
54Russell Investments Group, Ltd.3900 (0.00%)0.00%$0 MNov 6, 2026
55Nisa Investment Advisors, LLC361+26 (+7.76%)0.00%$0 MOct 20, 2026
56Farmers & Merchants Investments Inc300New0.00%$0 MOct 22, 2026
57Rothwell Investment Advisors, LLC300—0.00%$0 MNov 6, 2026
58Jones Financial Companies Lllp1850 (0.00%)0.00%$0 MNov 13, 2026
59Steigerwald, Gordon & Koch Inc.1200 (0.00%)0.00%$0 MNov 12, 2026
60UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC104New0.00%$0 MNov 16, 2026
61Physician Wealth Advisors, Inc.35New0.00%$0 MOct 20, 2026
62Tower Research Capital LLC (TRC)17New0.00%$0 MNov 16, 2026
63Dogwood Wealth Management LLC14New0.00%$0 MNov 9, 2026
64SBI Securities Co., Ltd.100 (0.00%)0.00%$0 MOct 22, 2026
65Pinnacle Wealth Planning Services, Inc.1New0.00%$0 MOct 27, 2026

Mutual funds holding BrainsWay Ltd.#

14 funds hold shares worth $12 M (about 2.0% of the company). Since their previous reports 8 added shares and 1 sold, buying $2 M net.
Mutual funds holding BrainsWay Ltd.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Timothy Plan Israel Common Values FundTimothy Partners, Ltd.182,606$3 M0.46%1.4%+5.8%Jun 30, 2026
🇺🇸 ARK Israel Innovative Technology ETFARK Investment Management LLC146,850$2 M0.37%1.6%+3.1%Jul 31, 2026
🇺🇸 1290 Essex Small Cap Growth FundEquitable Investment Management, LLC138,592$2 M0.35%1.8%no changeJul 31, 2026
🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP97,000$2 M0.25%0.63%no changeJun 30, 2026
🇺🇸 Amplify BlueStar Israel Technology ETFAmplify ETF Trust74,453$1 M0.19%0.96%newJun 30, 2026
🇺🇸 Old Westbury Small & Mid Cap Strategies FundBessemer Investment Management LLC50,627$1 M0.13%<0.01%no changeJul 31, 2026
🇺🇸 Steward Values Enhanced International FundCrossmark Global Investments25,351$0 M0.06%0.11%no changeJul 31, 2026
🇺🇸 ActivePassive International Equity ETFTrust for Professional Managers19,005$0 M0.05%0.03%+14%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC13,705$0 M0.03%<0.01%+173%May 31, 2026
🇺🇸 Voya Multi-Manager International Small Cap FundVoya Investments, LLC9,834$0 M0.02%0.03%no changeJul 31, 2026
🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors8,610$0 M0.02%0.02%+2.1%Jul 31, 2026
🇺🇸 SIT International Equity FundSEI INVESTMENTS MANAGEMENT CORPORATION6,021$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Siit World Equity Ex-Us FundSEI INVESTMENTS MANAGEMENT CORPORATION2,950$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC800$0 M<0.01%<0.01%−11%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at BrainsWay Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
0
0 purchases, 0 insiders
Sold, 12 months
0
7 sales, 3 insiders
Net, 12 months
0
open market only
Insiders on file
3
since

Too few open-market trades to chart.

BrainsWay Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gilad MoiseyevChief Technology OfficerSell-5,000——local53,098Form 4
filed Yiftach RothChief ScientistSell-1,000——local1.07 MForm 4
filed Yiftach RothChief ScientistSell-2,000——local1.07 MForm 4
filed Yiftach RothChief ScientistSell-2,000——local1.08 MForm 4
filed Yiftach RothChief ScientistSell-2,000——local1.08 MForm 4
filed Mitrany Rayten Michal EtyDirectorSell-7,980——local12,500Form 4
filed Gilad MoiseyevChief Technology OfficerOption exercise+7,500——local60,000Form 4
filed Gilad MoiseyevChief Technology OfficerShares withheld for tax-1,902——local58,098Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: BrainsWay Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
199,353
2.48 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 100 shares at $11.46
  • : 386 shares at $14.27
  • : 229 shares at $14.19
  • : 230 shares at $14.97
  • : 56 shares at $16.32

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

BrainsWay Ltd. scorecard#

Passes 8 of the 12 checks that could be worked out: strongest in growth (5 of 6), weakest in profitability (3 of 5). Fiscal year 2024; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth5 of 6
    • ✓Revenue grew in the newest year29.1%Revenue up 29.1% in fiscal 2024.
    • ✓Revenue up more than 5% a year over three years11.4%11.4% a year over the three years to fiscal 2024.
    • ✓Faster growth over three years than its peers' median11.4%11.4% a year against Healthcare's median of 8.5% (549 companies).
    • ✓Earnings per share grew in the newest year0.05 vs -0.13Diluted EPS 0.05 in fiscal 2024 against -0.13 the year before (report's currency).
    • ✓Net income higher than five years earlier$3 M$3 M in fiscal 2024 against -$10 M in 2019.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2024.
  • Profitability3 of 5
    • ✓Profitable in the newest year$3 MNet income $3 M in fiscal 2024.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
    • ✓Operating margin above its peers' median3.4%3.4% against Healthcare's median of -7.7% (674 companies).
    • ✗Return on equity above 15%5.6%5.6% in fiscal 2024.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier3.4%3.4% in fiscal 2024 against -16.9% in 2021.
  • Financial health0 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from BrainsWay Ltd.'s statements, beside the median of Healthcare.

BrainsWay Ltd.: main financial ratios in 2024
Ratio2024Median of peers
Operating margin3.4%-7.7%
Net margin7.1%-8.1%
Return on equity5.6%-36.9%
Revenue growth, 3 years a year11.4%8.5%
Revenue growth29.1%10.2%

5of 7on the Piotroski tests of financial strength

BrainsWay Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

BrainsWay Ltd.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue4132273022231611
Cost of revenue108.37.16.65.15.13.62.6
Gross profit312320231718138.6
Research and development7.26.77.76.45.87.96.25.3
Selling and marketing1616181611138.36.3
Total costs and expenses2928332822261815
Operating income1.4−5.0−13−5.0−4.8−8.5−5.1−6.6
Interest and finance income3.62.21.10.3————
Interest expense and finance costs1.51.2r1.5r−1.7r0.31.41.20.3
Income before tax3.5−3.9−13−6.4−5.1−9.9−6.3−6.9
Income tax0.50.30.30.00.20.40.20.2
Net income including minority interests2.9−4.2−13−6.5−5.4−10−6.5−7.1
Earnings per share, basic0.09-0.13-0.40-0.21————
Earnings per share, diluted0.05-0.13-0.40-0.21————
Shares, weighted average (basic)3433333122211715
Balance sheet
Cash and cash equivalents6911481717229.015
Inventory4.43.73.8—————
Other current assets1.01.71.61.81.5———
Current assets80555865242913—
Property, plant and equipment————4.44.22.9—
Right-of-use (leased) assets5.50.4——————
Non-current assets157.56.4109.79.910—
Total assets94636476343924—
Accounts payable5.95.3r4.54.83.83.43.5—
Current liabilities159.88.19.16.86.78.3—
Long-term debt——————2.1—
Lease liabilities (non-current)4.80.20.30.30.20.7——
Non-current liabilities1712119.37.67.88.3—
Retained earnings−98−101−97−84−77−72−62—
Total equity6242455720247.013
Total liabilities and equity94636476343924—
Shares outstanding38333333222217—
Cash-flow statement
Depreciation and amortization0.70.40.60.60.4r0.6r0.50.4
Share-based compensation1.40.41.51.90.81.30.71.0
Cash from operating activities101.3−9.80.9−1.4−7.2−3.8−3.5
Capital expenditure———−2.2−2.5−3.3−2.0−1.0
Cash from investing activities30−3742−42−2.5−2.4−1.1−2.5
Debt issued—————−3.0—2.7
Shares issued——−0.142—26—8.4
Cash from financing activities18−1.0−1.542−1.022−0.311
Exchange-rate effect on cash−0.00.1−0.2−0.20.2−0.1−0.40.1
Change in cash59−3731−0.0−4.713−5.55.3
Report20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where BrainsWay Ltd. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

BrainsWay Ltd.: countries of operation
CountryPresenceRevenue there
🇮🇱 IsraelHeadquarters1 office—
🇵🇸 Palestine1 office—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Acquisitions and funding#

Private share sales · funding history

Private share sales of BrainsWay Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2024$20 MPrivate placement after listing$10 to $50 million1equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Discuss BrainsWay Ltd.#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Mutual funds: 14 funds hold $12 millionautomatic update · Jul 31, 2026

    14 mutual funds in 1 country hold shares of BrainsWay Ltd. worth $12 million, about 2.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 8 funds added shares and 1 sold; on balance they bought $2 million. Share splits are not counted as trading.

How BrainsWay Ltd. compares in Healthcare

  • Market cap$602 M · higher than 48% of 2,013
  • Revenue$41 M · higher than 32% of 1,795
  • Net margin7.1% · higher than 62% of 1,485
  • Revenue growth29.1% · higher than 76% of 1,003
  • P/E ratio206.0× · lower than 4% of 605
  • Price / sales14.7× · lower than 16% of 1,071
  • Price / book9.7× · lower than 14% of 1,245
  • FCF yield-0.2% · higher than 66% of 835
CompanyMarket capP/ENet marginRev. growth
BrainsWay Ltd.🇮🇱$602 M206.0×7.1%+29.1%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BrainsWay Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BrainsWay Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BrainsWay Ltd.? Suggest a correction